Does Jardiance Cause Weight Loss? Clinical Evidence and What to Expect

Understanding Jardiance and Its Effects on Body Weight

Jardiance (empagliflozin) is a prescription medication primarily used to treat type 2 diabetes and reduce cardiovascular risks in certain patients. You may wonder whether this medication affects body weight as a side effect. Based on clinical evidence, Jardiance does typically cause modest weight loss in people with type 2 diabetes, though it is not approved or intended as a weight-loss medication.

The weight loss associated with Jardiance occurs as a secondary effect of how the medication works to control blood sugar levels. Understanding this relationship can help patients set realistic expectations about potential weight changes while taking this medication.

How Jardiance Works and Why Weight Loss Occurs

Jardiance belongs to a class of medications called SGLT2 inhibitors. These drugs work by blocking a protein in the kidneys that normally reabsorbs glucose from the urine back into the bloodstream. When this protein is blocked, excess glucose is eliminated through urination instead of being retained in the body.

This process of losing glucose through urine leads to weight loss because glucose contains calories. When the body eliminates approximately 200 to 400 calories’ worth of glucose daily through urine, this caloric loss can result in gradual weight reduction over time. The weight loss is not from fat burning or appetite suppression, but rather from the direct loss of glucose calories that would otherwise be stored or used by the body.

Clinical Trial Evidence on Weight Loss

Multiple clinical studies have measured the weight loss effects of Jardiance in people with type 2 diabetes. In pooled data from phase 3 trials, patients taking 10 mg of Jardiance experienced an average body weight reduction of 2.5 percent, which equals approximately 4.5 pounds for someone weighing around 180 pounds. Those taking the 25 mg dose saw slightly greater weight loss at 2.8 percent, or about 5.1 pounds for the same baseline weight.

However, the manufacturer clearly states that Jardiance is not made to lower body weight, even though weight loss can occur as a secondary effect.

Systematic reviews of randomized controlled trials show that weight loss with empagliflozin is consistently greater compared to placebo across multiple studies. All treatment groups experienced some weight reduction, but the weight loss was more pronounced in patients taking Jardiance versus those receiving a placebo.

What to Expect: Timeline and Amount of Weight Loss

The weight loss from Jardiance typically begins within the first few weeks of treatment as the medication reaches steady levels in the body. Most clinical studies measure weight changes at 24 weeks, showing that the majority of weight loss occurs within the first six months of treatment.

For context, a 2.5 to 2.8 percent weight loss means someone weighing 200 pounds might lose 5 to 6 pounds, while someone weighing 150 pounds might lose about 4 pounds. This is considered modest weight loss compared to medications specifically designed for weight management.

The weight loss tends to stabilize after the initial months rather than continuing indefinitely. This plateau occurs because the body adjusts to the new glucose excretion pattern, and the caloric loss from glucose elimination remains relatively constant.

Important Distinctions About Jardiance and Weight Management

While Jardiance does cause weight loss in clinical trials, several important points distinguish it from dedicated weight loss medications:

Primary Purpose: Jardiance is FDA-approved for treating type 2 diabetes and reducing cardiovascular death risk in adults with type 2 diabetes and heart disease. Weight loss is a secondary effect, not the primary therapeutic goal.

Mechanism Difference: Unlike weight loss medications that work through appetite suppression or fat absorption blocking, Jardiance causes weight loss solely through glucose elimination in urine.

Patient Population: The weight loss data comes from studies in people with type 2 diabetes. The effects in people without diabetes are not well-studied, and the medication is not prescribed for weight loss alone.

Factors That May Influence Weight Loss Results

Several factors can affect how much weight loss an individual experiences while taking Jardiance:

Baseline Blood Sugar Control: People with higher initial blood glucose levels may eliminate more glucose in their urine, potentially leading to more weight loss initially.

Diet and Lifestyle: Patients who maintain consistent eating habits are more likely to see the weight loss effects from glucose elimination. Those who increase caloric intake might offset some of the weight loss.

Other Medications: Some diabetes medications can cause weight gain, which might counteract the weight-loss effects of Jardiance when used in combination.

Individual Response: As with any medication, individual responses vary. Some people may experience more or less weight loss than the average seen in clinical trials.

Common Side Effects vs Serious but Rare Side Effects

Common Side Effects: The most frequently reported side effects of Jardiance include urinary tract infections, yeast infections, and increased urination. These effects are generally mild and manageable.

Serious but Rare Side Effects: Serious complications are uncommon but can include diabetic ketoacidosis, severe kidney problems, and severe dehydration. These occur in less than 1 percent of patients but require immediate medical attention if symptoms develop.

The modest weight loss experienced by most patients is considered a beneficial side effect rather than a harmful one, especially since many people with type 2 diabetes benefit from weight reduction.

Comparing Jardiance to Other Diabetes Medications

When compared to other diabetes medications, Jardiance falls into a category that typically promotes weight loss or weight neutrality rather than weight gain. This contrasts with some older diabetes medications like insulin or sulfonylureas, which can contribute to weight gain.

Other SGLT2 inhibitors work through similar mechanisms and also typically cause modest weight loss. However, the specific amount and timeline can vary between different medications in this class.

Some newer diabetes medications, particularly GLP-1 receptor agonists like Ozempic (semaglutide), tend to cause more significant weight loss than Jardiance, though through different mechanisms involving appetite regulation.

Cost Considerations and Accessibility

The cost of Jardiance can vary significantly depending on insurance coverage and pharmacy choice. For patients concerned about medication costs, exploring cash-pay options through reputable sources like Universal Drugstore may provide more affordable access to this medication.

When considering the financial aspect of treatment, patients should weigh the potential benefits of modest weight loss alongside the primary diabetes management benefits when discussing cost-effectiveness with their healthcare provider.

Who Should Consider Jardiance for Diabetes Management

Jardiance may be particularly suitable for people with type 2 diabetes who would benefit from weight loss as a secondary effect. However, the decision should always be based primarily on diabetes management needs rather than weight loss goals.

Healthcare providers typically consider Jardiance for patients with type 2 diabetes who need additional blood sugar control, have cardiovascular risk factors, or have not achieved target glucose levels with other medications. The potential for modest weight loss can be an additional benefit but should not be the primary reason for prescribing.

Setting Realistic Expectations

Patients considering Jardiance should understand that while weight loss does occur, it is modest and primarily serves to support overall diabetes management rather than achieve significant weight reduction. The 2.5 to 2.8 percent weight loss seen in clinical trials represents a meaningful but limited effect.

For people seeking substantial weight loss, dedicated weight management strategies, including lifestyle modifications, dietary changes, and potentially medications specifically approved for weight loss, may be more appropriate.

The weight loss from Jardiance should be viewed as a beneficial addition to its primary diabetes management effects rather than as a primary weight loss intervention. This perspective helps ensure that treatment decisions are made based on comprehensive health goals rather than single outcomes.

References

• Jardiance T2D Efficacy Data. Boehringer Ingelheim. Accessed May 28, 2026.
• Jardiance- empagliflozin tablet, film-coated [package insert]. DailyMed. Boehringer Ingelheim. Last updated 1/2026. Accessed May 28, 2026.
• Clinical Review Report: Empagliflozin (Jardiance). NCBI Bookshelf. Accessed May 28, 2026.